Literature DB >> 21625959

hnRNP F directs formation of an exon 4 minus variant of tumor-associated NADH oxidase (ENOX2).

Xiaoyu Tang1, Vanessa D Kane, Dorothy M Morré, D James Morré.   

Abstract

HUVEC or mouse 3T3 cells infected with SV-40 generate within 3 to 5 days post-infection an ENOX2 species corresponding to the exon-4 minus splice variant of a tumor-associated NADH oxidase (ENOX2 or tNOX) expressed at the cancer cell surface. This study was to seek evidence for splicing factors that might direct formation of the exon 4 minus ENOX2 splice variant. To determine if silencing of ENOX2 exon 4 occurs because of motifs located in exon 4, transfections were performed on MCF-10A (mammary non-cancer), BT-20 (mammary cancer), and HeLa (cervical cancer) cells using a GFP minigene construct containing either a constitutively spliced exon (albumin exon 2) or the alternatively spliced ENOX2 exon 4 between the two GFP halves. Removal of exon 4 from the processed RNA of the GFP minigene construct occurred with HeLa and to a lesser extent with BT-20 but not in non-cancer MCF-10A cells. The Splicing Rainbow Program was used to identify all of the possible hnRNPs binding sites of exon 4 of ENOX2. There are 8 Exonic Splicing Silencers (ESSs) for hnRNP binding in the exon 4 sequences. Each of these sites were mutated by site-directed mutagenesis to test if any were responsible for the splicing skip. Results showed MutG75 ESS mutation changed the GFP expression which is a sign of splicing silence, while other mutations did not. As MutG75 changed the ESS binding site for hnRNP F, this result suggests that hnRNP F directs formation of the exon 4 minus variant of ENOX2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21625959     DOI: 10.1007/s11010-011-0875-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H'/F/2H9 family.

Authors:  M Caputi; A M Zahler
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

2.  An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon.

Authors:  Sushma-Nagaraja Grellscheid; Christopher W J Smith
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  NADH oxidase activity from sera altered by capsaicin is widely distributed among cancer patients.

Authors:  D J Morré; S Caldwell; A Mayorga; L Y Wu; D M Morré
Journal:  Arch Biochem Biophys       Date:  1997-06-15       Impact factor: 4.013

4.  A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.

Authors:  D J Morré; T Reust
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

5.  Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture.

Authors:  D J Morré; A Bridge; L Y Wu; D M Morré
Journal:  Biochem Pharmacol       Date:  2000-10-01       Impact factor: 5.858

6.  tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate.

Authors:  Pin-Ju Chueh; Lian-Ying Wu; Dorothy M Morré; D James Morré
Journal:  Biofactors       Date:  2004       Impact factor: 6.113

7.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene.

Authors:  Rotem Karni; Elisa de Stanchina; Scott W Lowe; Rahul Sinha; David Mu; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

8.  The hnRNP F protein: unique primary structure, nucleic acid-binding properties, and subcellular localization.

Authors:  M J Matunis; J Xing; G Dreyfuss
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

9.  Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues.

Authors:  Bent Honoré; Ulrik Baandrup; Henrik Vorum
Journal:  Exp Cell Res       Date:  2004-03-10       Impact factor: 3.905

10.  A G-tract element in apoptotic agents-induced alternative splicing.

Authors:  Yan Hai; Wenguang Cao; Guodong Liu; Say-Pham Hong; Sherif Abou Elela; Roscoe Klinck; Jiayou Chu; Jiuyong Xie
Journal:  Nucleic Acids Res       Date:  2008-04-24       Impact factor: 16.971

View more
  4 in total

1.  Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms.

Authors:  Timothy A Vickers; Stanley T Crooke
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 2.  Alternative Splicing as a Target for Cancer Treatment.

Authors:  Nancy Martinez-Montiel; Nora Hilda Rosas-Murrieta; Maricruz Anaya Ruiz; Eduardo Monjaraz-Guzman; Rebeca Martinez-Contreras
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923

3.  ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.

Authors:  Song-Hui Xu; Song Zhu; Yanjie Wang; Jin-Zhou Huang; Min Chen; Qing-Xia Wu; Yu-Tian He; Guang-Rong Yan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

Review 4.  The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer.

Authors:  Andrea Cerasuolo; Luigi Buonaguro; Franco M Buonaguro; Maria Lina Tornesello
Journal:  Front Cell Dev Biol       Date:  2020-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.